5[4]WHO & WPRO,Immunization Safety Surveillance:Guidelines for Managers of Immunization Programmes on Reporting and Investigating Adverse Events Following Immunization[M].Manila,Phillipines,1999. 被引量：1
6[5]Matthew M,Nikki T.Suggestions for improving the monitoring of adverse events following immunization in New Zealand[J].New Engl J Med.2002,115:1162-1166. 被引量：1
7Tarvin SE, Ballinger S. Henoch-Schonlein purpura[J]. Current Paediatrics, 2006, 16: 259-263. 被引量：1
8Gardner-Medwin JMM, Dolezalova P, Cummins C, et al. Incidence of Henoch-SchSnlein purpura; Kawasaki disease, and rare vasculitides in children of different ethnic origins[J]. Lancet, 2002, 360: 1197-1202. 被引量：1
9Pless RP, Bentsi-Enchill AD, Duclos P, et al. Monitoring Vaccine Safety during Measles Mass Immunization Campaigns: Clinical and Programmatic Issues [J]. The Journal of Infectious Diseases, 2003, 187(Suppl1): S291-298. 被引量：1
10Weigong Z, Vitali P, John KI, et al, Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS) --United States, 1991-9001 [J]. MMWR, 2003,52(No. SS-1):1-24. 被引量：1
